Related Experiment Video

Updated: Aug 23, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Increased soluble CD40L levels are reduced by long-term simvastatin treatment in peritoneally dialyzed patients

Jolanta Malyszko1, Jacek S Malyszko, Tomasz Hryszko

  • 1Nephrology and Transplantology Department, Medical University, 15-540 Bialystok, Zurawia 14, Poland. jolmal@poczta.onet.pl

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|August 18, 2004
PubMed

Insights

Simvastatin treatment in peritoneal dialysis patients significantly reduced soluble CD40 ligand (sCD40L) and improved endothelial dysfunction. This suggests statins may downregulate CD40-CD40 ligand interactions in this population.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • Cardiovascular events and dyslipidemia are prevalent in continuous ambulatory peritoneal dialysis (CAPD) patients.
  • Statins are known to improve lipid profiles and reduce cardiovascular mortality.
  • The CD40-CD40 ligand (CD40L) system's role in endothelial activation is implicated, with potential statin-mediated downregulation, but data in CAPD patients is limited.

Purpose of the Study:

  • To investigate the impact of simvastatin on platelet aggregation, endothelial injury markers, and soluble CD40L (sCD40L) in hyperlipidemic CAPD patients.
  • To assess the effects of a 6-month simvastatin regimen.

Main Methods:

  • A prospective study involving 15 hyperlipidemic CAPD patients.
  • Treatment with simvastatin 10 mg daily for 6 months.

Main Results:

  • A significant decrease in sCD40L was observed after 6 months of simvastatin therapy.
  • Thrombomodulin levels decreased significantly after 3 months.
  • No significant changes were noted in von Willebrand factor, E-selectin, or P-selectin.

Conclusions:

  • Simvastatin therapy effectively reduced elevated sCD40L levels and ameliorated endothelial dysfunction in CAPD patients.
  • Simvastatin may play a role in downregulating CD40-CD40L interactions, contributing to cardiovascular risk reduction in this patient group.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...